Puma Biotechnology (PBYI) Profit After Tax Growth (3y) (2013 - 2026)

Puma Biotechnology (PBYI) Profit After Tax Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.53%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -27.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 70.25%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Puma Biotechnology 409.56 Mn 371.27 Mn 34.39 Mn -67.25%

Historic Data

Download Data
DateValue
Mar 31, 2026 -67.25%
Dec 31, 2025 63.83%
Sep 30, 2025 198.39%
Jun 30, 2025 -14.51%
Mar 31, 2025 42.18%
Dec 31, 2024 65.95%
Sep 30, 2024 34.90%
Jun 30, 2024 3.92%
Mar 31, 2024 -31.83%
Dec 31, 2023 41.25%
Sep 30, 2023 29.75%
Jun 30, 2023 -14.45%
Mar 31, 2023 27.71%
Dec 31, 2022 20.60%
Sep 30, 2022 72.27%
Jun 30, 2022 31.04%
Mar 31, 2022 30.39%
Dec 31, 2021 28.82%
Sep 30, 2021 -46.52%
Jun 30, 2021 51.35%